Taken together, these data revealed that TFRC-targeted TF-Fe3+ NVs combined with SOR synergistically induced ample ferroptotic responses in TFRC-overexpressing HCC cells, with an enhanced therapeutic effect compared to the single drug treatment. This evidence concerns the gene TF and hepatocellular carcinoma.